Michael T Barbe1, Paul Reker2, Stefanie Hamacher2, Jeremy Franklin2, Daria Kraus2, Till A Dembek2, Johannes Becker2, Julia K Steffen2, Niels Allert2, Jochen Wirths2, Haidar S Dafsari2, Jürgen Voges2, Gereon R Fink2, Veerle Visser-Vandewalle2, Lars Timmermann2. 1. From the Department of Neurology (M.T.B., P.R., T.A.D., J.B., J.K.S., H.S.D., G.R.F., L.T.) and Department of Stereotaxy and Functional Neurosurgery (T.A.D., J.W., V.V.-V.), University Hospital of Cologne; Institute of Medical Statistics and Computational Biology (S.H., J.F.) and Clinical Trials Center Cologne (D.K.), University of Cologne; Neurological Rehabilitation Center Godeshöhe (N.A.), Bonn, Germany; National Parkinson Foundation International Centre of Excellence (H.S.D.), Kings College Hospital, London, UK; Department of Stereotactic Neurosurgery (J.V.), Otto-von-Guericke University Magdeburg and Leibniz Institute for Neurobiology; Cognitive Neuroscience (G.R.F.), Institute of Neuroscience and Medicine (INM-3), Research Centre Jülich; and Department of Neurology (L.T.), University Hospital Marburg, Germany michael.barbe@uk-koeln.de. 2. From the Department of Neurology (M.T.B., P.R., T.A.D., J.B., J.K.S., H.S.D., G.R.F., L.T.) and Department of Stereotaxy and Functional Neurosurgery (T.A.D., J.W., V.V.-V.), University Hospital of Cologne; Institute of Medical Statistics and Computational Biology (S.H., J.F.) and Clinical Trials Center Cologne (D.K.), University of Cologne; Neurological Rehabilitation Center Godeshöhe (N.A.), Bonn, Germany; National Parkinson Foundation International Centre of Excellence (H.S.D.), Kings College Hospital, London, UK; Department of Stereotactic Neurosurgery (J.V.), Otto-von-Guericke University Magdeburg and Leibniz Institute for Neurobiology; Cognitive Neuroscience (G.R.F.), Institute of Neuroscience and Medicine (INM-3), Research Centre Jülich; and Department of Neurology (L.T.), University Hospital Marburg, Germany.
Abstract
OBJECTIVE: To evaluate deep brain stimulation (DBS) of the posterior subthalamic area (PSA) in essential tremor (ET) and compare it to the ventral intermediate nucleus of the thalamus (VIM) in terms of stimulation efficacy, efficiency, and side effects. METHODS: DBS leads were implanted such that contacts were placed in the VIM, on the intercommissural line, and in the PSA. Thirteen patients with ET entered a randomized, double-blind crossover phase and completed a 1-year follow-up. RESULTS:PSA-DBS significantly reduced tremor severity and improved quality of life. There were no relevant differences in quality and frequency of stimulation side effects between VIM and PSA, with a tendency toward greater tremor improvement with PSA stimulation. Clinical benefit was achieved at significantly lower stimulation amplitudes in the PSA. The majority of patients remained with PSA-DBS after 1 year. CONCLUSION: In accordance with previous retrospective investigations, our prospective data suggest that PSA-DBS is at least equally effective as but possibly more efficient than VIM-DBS. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with essential tremor, PSA-DBS is not significantly different from VIM-DBS in suppressing tremor, but clinical benefit from PSA-DBS is attained at lower stimulation amplitudes.
RCT Entities:
OBJECTIVE: To evaluate deep brain stimulation (DBS) of the posterior subthalamic area (PSA) in essential tremor (ET) and compare it to the ventral intermediate nucleus of the thalamus (VIM) in terms of stimulation efficacy, efficiency, and side effects. METHODS: DBS leads were implanted such that contacts were placed in the VIM, on the intercommissural line, and in the PSA. Thirteen patients with ET entered a randomized, double-blind crossover phase and completed a 1-year follow-up. RESULTS:PSA-DBS significantly reduced tremor severity and improved quality of life. There were no relevant differences in quality and frequency of stimulation side effects between VIM and PSA, with a tendency toward greater tremor improvement with PSA stimulation. Clinical benefit was achieved at significantly lower stimulation amplitudes in the PSA. The majority of patients remained with PSA-DBS after 1 year. CONCLUSION: In accordance with previous retrospective investigations, our prospective data suggest that PSA-DBS is at least equally effective as but possibly more efficient than VIM-DBS. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with essential tremor, PSA-DBS is not significantly different from VIM-DBS in suppressing tremor, but clinical benefit from PSA-DBS is attained at lower stimulation amplitudes.
Authors: Sina R Potel; Sara Marceglia; Sara Meoni; Suneil K Kalia; Rubens G Cury; Elena Moro Journal: Curr Neurol Neurosci Rep Date: 2022-07-15 Impact factor: 6.030
Authors: Joshua K Wong; Christopher W Hess; Leonardo Almeida; Erik H Middlebrooks; Evangelos A Christou; Erin E Patrick; Aparna Wagle Shukla; Kelly D Foote; Michael S Okun Journal: Expert Rev Neurother Date: 2020-03-02 Impact factor: 4.618
Authors: B J Wilkes; A Wagle Shukla; A Casamento-Moran; C W Hess; E A Christou; M S Okun; D E Vaillancourt Journal: Clin Neurophysiol Date: 2019-11-20 Impact factor: 3.708
Authors: Myung Ji Kim; Kyung Won Chang; So Hee Park; Won Seok Chang; Hyun Ho Jung; Jin Woo Chang Journal: Front Neurol Date: 2021-06-09 Impact factor: 4.003